A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Nab-paclitaxel
Related studies linked through entity extraction aliases.
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LY3200882 in Participants With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
- Status
- COMPLETED
- Phase
- PHASE2
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
- Status
- COMPLETED
- Phase
- PHASE3
Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE4
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC
- Status
- COMPLETED
- Phase
- N/A
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE1
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
- Status
- COMPLETED
- Phase
- PHASE3